Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Jul;80(9):1445–1452. doi: 10.1038/sj.bjc.6690542

Molecular epidemiological study of non-small-cell lung cancer from an environmentally polluted region of Poland

M Rusin 1, D Butkiewicz 1, E Malusecka 1, A Zborek 1, J Harasim 2, K Czyzewski 2, W P Bennett 1, P G Shields 3, A Weston 4, J A Welsh 3, S Krzyzowska-Gruca 1, M Chorazy 1, C C Harris 3
PMCID: PMC2363079  PMID: 10424749

Abstract

The p53 mutation spectrum can generate hypotheses linking carcinogen exposure to human cancer. Although it is well-documented that tobacco smoking is a major cause of lung cancer, the contribution of air pollution is less well-established. We determined the molecular and immunohistochemical changes (p53 gene mutations, p53 protein accumulation and WAF1 protein expression) and genetic polymorphisms of GSTM1, CYP1A1 and CYP2D6 genes in a case series of non-small-cell lung cancers from Silesia. This region of southern Poland is highly industrialized with considerable environmental pollution. More than 50% of lung cancers (90/164) contained p53 mutations and 75% showed the combined alteration of the p53 gene and protein accumulation. Males occupationally exposed to coal-derived substances showed a relatively high frequency of squamous and large-cell carcinomas, relatively frequent mutations in codon 298 of p53 and a low frequency of p53 immunohistochemically positive tumours. Codon 298 GAG→ →TAG mutations have rarely been found in lung cancers in other populations. We found no correlation between WAF1 protein expression and mutations in the p53 gene or p53 protein accumulation. No statistically significant relationship was found between p53 mutations and GSTM1, CYP1A1, CYP2D6 genotypes. Never smokers with lung cancers from Silesia had a higher frequency of G:C→ →T:A transversions than previously reported of the p53 mutation spectrum in never smokers (6/15 vs 4/34; P = 0.06 by χ2). These data are a tentative indication that occupational and environmental exposure to polycyclic aromatic hydrocarbons, such as benzo(a)pyrene, in polluted air contributes to the molecular pathogenesis of lung cancer in never smokers. © 1999 Cancer Research Campaign

Keywords: p53, WAF1, GSTM1;, CYP1A1;, CYP2D6, tobacco smoke

Full Text

The Full Text of this article is available as a PDF (108.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alexandrie A. K., Sundberg M. I., Seidegård J., Tornling G., Rannug A. Genetic susceptibility to lung cancer with special emphasis on CYP1A1 and GSTM1: a study on host factors in relation to age at onset, gender and histological cancer types. Carcinogenesis. 1994 Sep;15(9):1785–1790. doi: 10.1093/carcin/15.9.1785. [DOI] [PubMed] [Google Scholar]
  2. Ayesh R., Idle J. R., Ritchie J. C., Crothers M. J., Hetzel M. R. Metabolic oxidation phenotypes as markers for susceptibility to lung cancer. Nature. 1984 Nov 8;312(5990):169–170. doi: 10.1038/312169a0. [DOI] [PubMed] [Google Scholar]
  3. Bennett W. P., Colby T. V., Travis W. D., Borkowski A., Jones R. T., Lane D. P., Metcalf R. A., Samet J. M., Takeshima Y., Gu J. R. p53 protein accumulates frequently in early bronchial neoplasia. Cancer Res. 1993 Oct 15;53(20):4817–4822. [PubMed] [Google Scholar]
  4. Bennett W. P., el-Deiry W. S., Rush W. L., Guinee D. G., Jr, Freedman A. N., Caporaso N. E., Welsh J. A., Jones R. T., Borkowski A., Travis W. D. p21waf1/cip1 and transforming growth factor beta 1 protein expression correlate with survival in non-small cell lung cancer. Clin Cancer Res. 1998 Jun;4(6):1499–1506. [PubMed] [Google Scholar]
  5. Caporaso N., Hayes R. B., Dosemeci M., Hoover R., Ayesh R., Hetzel M., Idle J. Lung cancer risk, occupational exposure, and the debrisoquine metabolic phenotype. Cancer Res. 1989 Jul 1;49(13):3675–3679. [PubMed] [Google Scholar]
  6. Cariello N. F., Piegorsch W. W., Adams W. T., Skopek T. R. Computer program for the analysis of mutational spectra: application to p53 mutations. Carcinogenesis. 1994 Oct;15(10):2281–2285. doi: 10.1093/carcin/15.10.2281. [DOI] [PubMed] [Google Scholar]
  7. Cholerton S., Arpanahi A., McCracken N., Boustead C., Taber H., Johnstone E., Leathart J., Daly A. K., Idle J. R. Poor metabolisers of nicotine and CYP2D6 polymorphism. Lancet. 1994 Jan 1;343(8888):62–63. doi: 10.1016/s0140-6736(94)90921-0. [DOI] [PubMed] [Google Scholar]
  8. Chorazy M., Szeliga J., Strózyk M., Cimander B. Ambient air pollutants in upper Silesia: partial chemical composition and biological activity. Environ Health Perspect. 1994 Oct;102 (Suppl 4):61–66. doi: 10.1289/ehp.94102s461. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Crespi C. L., Penman B. W., Gelboin H. V., Gonzalez F. J. A tobacco smoke-derived nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, is activated by multiple human cytochrome P450s including the polymorphic human cytochrome P4502D6. Carcinogenesis. 1991 Jul;12(7):1197–1201. doi: 10.1093/carcin/12.7.1197. [DOI] [PubMed] [Google Scholar]
  10. Denissenko M. F., Pao A., Pfeifer G. P., Tang M. Slow repair of bulky DNA adducts along the nontranscribed strand of the human p53 gene may explain the strand bias of transversion mutations in cancers. Oncogene. 1998 Mar 12;16(10):1241–1247. doi: 10.1038/sj.onc.1201647. [DOI] [PubMed] [Google Scholar]
  11. Evans M. K., Taffe B. G., Harris C. C., Bohr V. A. DNA strand bias in the repair of the p53 gene in normal human and xeroderma pigmentosum group C fibroblasts. Cancer Res. 1993 Nov 15;53(22):5377–5381. [PubMed] [Google Scholar]
  12. Greenblatt M. S., Bennett W. P., Hollstein M., Harris C. C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994 Sep 15;54(18):4855–4878. [PubMed] [Google Scholar]
  13. Grzybowska E., Hemminki K., Choraźy M. Seasonal variations in levels of DNA adducts and X-spots in human populations living in different parts of Poland. Environ Health Perspect. 1993 Mar;99:77–81. doi: 10.1289/ehp.939977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Gualberto A., Aldape K., Kozakiewicz K., Tlsty T. D. An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control. Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):5166–5171. doi: 10.1073/pnas.95.9.5166. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Hainaut P., Hernandez T., Robinson A., Rodriguez-Tome P., Flores T., Hollstein M., Harris C. C., Montesano R. IARC Database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualisation tools. Nucleic Acids Res. 1998 Jan 1;26(1):205–213. doi: 10.1093/nar/26.1.205. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Harper J. W., Adami G. R., Wei N., Keyomarsi K., Elledge S. J. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 1993 Nov 19;75(4):805–816. doi: 10.1016/0092-8674(93)90499-g. [DOI] [PubMed] [Google Scholar]
  17. Harris C. C. p53 tumor suppressor gene: from the basic research laboratory to the clinic--an abridged historical perspective. Carcinogenesis. 1996 Jun;17(6):1187–1198. doi: 10.1093/carcin/17.6.1187. [DOI] [PubMed] [Google Scholar]
  18. Harris C. C. p53: at the crossroads of molecular carcinogenesis and risk assessment. Science. 1993 Dec 24;262(5142):1980–1981. doi: 10.1126/science.8266092. [DOI] [PubMed] [Google Scholar]
  19. Haupt Y., Maya R., Kazaz A., Oren M. Mdm2 promotes the rapid degradation of p53. Nature. 1997 May 15;387(6630):296–299. doi: 10.1038/387296a0. [DOI] [PubMed] [Google Scholar]
  20. Hayashi S., Watanabe J., Kawajiri K. High susceptibility to lung cancer analyzed in terms of combined genotypes of P450IA1 and Mu-class glutathione S-transferase genes. Jpn J Cancer Res. 1992 Aug;83(8):866–870. doi: 10.1111/j.1349-7006.1992.tb01992.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Heim M., Meyer U. A. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet. 1990 Sep 1;336(8714):529–532. doi: 10.1016/0140-6736(90)92086-w. [DOI] [PubMed] [Google Scholar]
  22. Hirvonen A., Husgafvel-Pursiainen K., Anttila S., Vainio H. The GSTM1 null genotype as a potential risk modifier for squamous cell carcinoma of the lung. Carcinogenesis. 1993 Jul;14(7):1479–1481. doi: 10.1093/carcin/14.7.1479. [DOI] [PubMed] [Google Scholar]
  23. Hollstein M., Sidransky D., Vogelstein B., Harris C. C. p53 mutations in human cancers. Science. 1991 Jul 5;253(5015):49–53. doi: 10.1126/science.1905840. [DOI] [PubMed] [Google Scholar]
  24. Hussain S. P., Harris C. C. Molecular epidemiology of human cancer: contribution of mutation spectra studies of tumor suppressor genes. Cancer Res. 1998 Sep 15;58(18):4023–4037. [PubMed] [Google Scholar]
  25. Iggo R., Gatter K., Bartek J., Lane D., Harris A. L. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet. 1990 Mar 24;335(8691):675–679. doi: 10.1016/0140-6736(90)90801-b. [DOI] [PubMed] [Google Scholar]
  26. Kato S., Bowman E. D., Harrington A. M., Blomeke B., Shields P. G. Human lung carcinogen-DNA adduct levels mediated by genetic polymorphisms in vivo. J Natl Cancer Inst. 1995 Jun 21;87(12):902–907. doi: 10.1093/jnci/87.12.902. [DOI] [PubMed] [Google Scholar]
  27. Kawajiri K., Eguchi H., Nakachi K., Sekiya T., Yamamoto M. Association of CYP1A1 germ line polymorphisms with mutations of the p53 gene in lung cancer. Cancer Res. 1996 Jan 1;56(1):72–76. [PubMed] [Google Scholar]
  28. Kihara M., Kihara M., Noda K. Lung cancer risk of GSTM1 null genotype is dependent on the extent of tobacco smoke exposure. Carcinogenesis. 1994 Feb;15(2):415–418. doi: 10.1093/carcin/15.2.415. [DOI] [PubMed] [Google Scholar]
  29. Ko L. J., Prives C. p53: puzzle and paradigm. Genes Dev. 1996 May 1;10(9):1054–1072. doi: 10.1101/gad.10.9.1054. [DOI] [PubMed] [Google Scholar]
  30. Kondo K., Tsuzuki H., Sasa M., Sumitomo M., Uyama T., Monden Y. A dose-response relationship between the frequency of p53 mutations and tobacco consumption in lung cancer patients. J Surg Oncol. 1996 Jan;61(1):20–26. doi: 10.1002/(SICI)1096-9098(199601)61:1<20::AID-JSO6>3.0.CO;2-U. [DOI] [PubMed] [Google Scholar]
  31. Kubbutat M. H., Jones S. N., Vousden K. H. Regulation of p53 stability by Mdm2. Nature. 1997 May 15;387(6630):299–303. doi: 10.1038/387299a0. [DOI] [PubMed] [Google Scholar]
  32. Kuempel E. D., Stayner L. T., Attfield M. D., Buncher C. R. Exposure-response analysis of mortality among coal miners in the United States. Am J Ind Med. 1995 Aug;28(2):167–184. doi: 10.1002/ajim.4700280203. [DOI] [PubMed] [Google Scholar]
  33. Legros Y., Lacabanne V., d'Agay M. F., Larsen C. J., Pla M., Soussi T. Production of human p53 specific monoclonal antibodies and their use in immunohistochemical studies of tumor cells. Bull Cancer. 1993 Feb;80(2):102–110. [PubMed] [Google Scholar]
  34. Lehman T. A., Bennett W. P., Metcalf R. A., Welsh J. A., Ecker J., Modali R. V., Ullrich S., Romano J. W., Appella E., Testa J. R. p53 mutations, ras mutations, and p53-heat shock 70 protein complexes in human lung carcinoma cell lines. Cancer Res. 1991 Aug 1;51(15):4090–4096. [PubMed] [Google Scholar]
  35. Levine A. J. p53, the cellular gatekeeper for growth and division. Cell. 1997 Feb 7;88(3):323–331. doi: 10.1016/s0092-8674(00)81871-1. [DOI] [PubMed] [Google Scholar]
  36. Meijers J. M., Swaen G. M., Slangen J. J., van Vliet K., Sturmans F. Long-term mortality in miners with coal workers' pneumoconiosis in The Netherlands: a pilot study. Am J Ind Med. 1991;19(1):43–50. doi: 10.1002/ajim.4700190106. [DOI] [PubMed] [Google Scholar]
  37. Miller A. B. Epidemiology, prevention, prognostic factors, and natural history of lung cancer. Curr Opin Oncol. 1992 Apr;4(2):286–291. doi: 10.1097/00001622-199204000-00009. [DOI] [PubMed] [Google Scholar]
  38. Miller B. G., Jacobsen M. Dust exposure, pneumoconiosis, and mortality of coalminers. Br J Ind Med. 1985 Nov;42(11):723–733. doi: 10.1136/oem.42.11.723. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Motykiewicz G., Małusecka E., Grzybowska E., Chorazy M., Zhang Y. J., Perera F. P., Santella R. M. Immunohistochemical quantitation of polycyclic aromatic hydrocarbon-DNA adducts in human lymphocytes. Cancer Res. 1995 Apr 1;55(7):1417–1422. [PubMed] [Google Scholar]
  40. Motykiewicz G., Michalska J., Pendzich J., Perera F. P., Chorazy M. A cytogenetic study of men environmentally and occupationally exposed to airborne pollutants. Mutat Res. 1992 Oct;280(4):253–259. doi: 10.1016/0165-1218(92)90055-5. [DOI] [PubMed] [Google Scholar]
  41. Nakachi K., Imai K., Hayashi S., Kawajiri K. Polymorphisms of the CYP1A1 and glutathione S-transferase genes associated with susceptibility to lung cancer in relation to cigarette dose in a Japanese population. Cancer Res. 1993 Jul 1;53(13):2994–2999. [PubMed] [Google Scholar]
  42. Perera F. P., Hemminki K., Gryzbowska E., Motykiewicz G., Michalska J., Santella R. M., Young T. L., Dickey C., Brandt-Rauf P., De Vivo I. Molecular and genetic damage in humans from environmental pollution in Poland. Nature. 1992 Nov 19;360(6401):256–258. doi: 10.1038/360256a0. [DOI] [PubMed] [Google Scholar]
  43. Petersen G. M. Epidemiology, screening, and prevention of lung cancer. Curr Opin Oncol. 1994 Mar;6(2):156–161. doi: 10.1097/00001622-199403000-00007. [DOI] [PubMed] [Google Scholar]
  44. Rebbeck T. R. Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol Biomarkers Prev. 1997 Sep;6(9):733–743. [PubMed] [Google Scholar]
  45. Ruggeri B., DiRado M., Zhang S. Y., Bauer B., Goodrow T., Klein-Szanto A. J. Benzo[a]pyrene-induced murine skin tumors exhibit frequent and characteristic G to T mutations in the p53 gene. Proc Natl Acad Sci U S A. 1993 Feb 1;90(3):1013–1017. doi: 10.1073/pnas.90.3.1013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Ryberg D., Kure E., Lystad S., Skaug V., Stangeland L., Mercy I., Børresen A. L., Haugen A. p53 mutations in lung tumors: relationship to putative susceptibility markers for cancer. Cancer Res. 1994 Mar 15;54(6):1551–1555. [PubMed] [Google Scholar]
  47. Shields P. G., Bowman E. D., Harrington A. M., Doan V. T., Weston A. Polycyclic aromatic hydrocarbon-DNA adducts in human lung and cancer susceptibility genes. Cancer Res. 1993 Aug 1;53(15):3486–3492. [PubMed] [Google Scholar]
  48. Sozzi G., Miozzo M., Donghi R., Pilotti S., Cariani C. T., Pastorino U., Della Porta G., Pierotti M. A. Deletions of 17p and p53 mutations in preneoplastic lesions of the lung. Cancer Res. 1992 Nov 1;52(21):6079–6082. [PubMed] [Google Scholar]
  49. Starzyński Z., Marek K., Kujawska A., Szymczak W. Mortality among different occupational groups of workers with pneumoconiosis: results from a register-based cohort study. Am J Ind Med. 1996 Dec;30(6):718–725. doi: 10.1002/(SICI)1097-0274(199612)30:6<718::AID-AJIM8>3.0.CO;2-M. [DOI] [PubMed] [Google Scholar]
  50. Stücker I., Cosme J., Laurent P., Cenée S., Beaune P., Bignon J., Depierre A., Milleron B., Hémon D. CYP2D6 genotype and lung cancer risk according to histologic type and tobacco exposure. Carcinogenesis. 1995 Nov;16(11):2759–2764. doi: 10.1093/carcin/16.11.2759. [DOI] [PubMed] [Google Scholar]
  51. Sugimura H., Caporaso N. E., Shaw G. L., Modali R. V., Gonzalez F. J., Hoover R. N., Resau J. H., Trump B. F., Weston A., Harris C. C. Human debrisoquine hydroxylase gene polymorphisms in cancer patients and controls. Carcinogenesis. 1990 Sep;11(9):1527–1530. doi: 10.1093/carcin/11.9.1527. [DOI] [PubMed] [Google Scholar]
  52. Takeshima Y., Seyama T., Bennett W. P., Akiyama M., Tokuoka S., Inai K., Mabuchi K., Land C. E., Harris C. C. p53 mutations in lung cancers from non-smoking atomic-bomb survivors. Lancet. 1993 Dec 18;342(8886-8887):1520–1521. doi: 10.1016/s0140-6736(05)80087-x. [DOI] [PubMed] [Google Scholar]
  53. Tefre T., Daly A. K., Armstrong M., Leathart J. B., Idle J. R., Brøgger A., Børresen A. L. Genotyping of the CYP2D6 gene in Norwegian lung cancer patients and controls. Pharmacogenetics. 1994 Apr;4(2):47–57. [PubMed] [Google Scholar]
  54. Vähäkangas K. H., Samet J. M., Metcalf R. A., Welsh J. A., Bennett W. P., Lane D. P., Harris C. C. Mutations of p53 and ras genes in radon-associated lung cancer from uranium miners. Lancet. 1992 Mar 7;339(8793):576–580. doi: 10.1016/0140-6736(92)90866-2. [DOI] [PubMed] [Google Scholar]
  55. Wang X., Christiani D. C., Wiencke J. K., Fischbein M., Xu X., Cheng T. J., Mark E., Wain J. C., Kelsey K. T. Mutations in the p53 gene in lung cancer are associated with cigarette smoking and asbestos exposure. Cancer Epidemiol Biomarkers Prev. 1995 Jul-Aug;4(5):543–548. [PubMed] [Google Scholar]
  56. Xiong Y., Hannon G. J., Zhang H., Casso D., Kobayashi R., Beach D. p21 is a universal inhibitor of cyclin kinases. Nature. 1993 Dec 16;366(6456):701–704. doi: 10.1038/366701a0. [DOI] [PubMed] [Google Scholar]
  57. el-Deiry W. S., Tokino T., Velculescu V. E., Levy D. B., Parsons R., Trent J. M., Lin D., Mercer W. E., Kinzler K. W., Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell. 1993 Nov 19;75(4):817–825. doi: 10.1016/0092-8674(93)90500-p. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES